VACOP-B, high-dose cyclophosphamide and high-dose therapy with peripheral blood progenitor cell rescue for aggressive non-Hodgkin's lymphoma with bone marrow involvement: A study by the non-Hodgkin's Lymphoma Co- operative Study Group

Haematologica

Volumn 85, Issue 2, 2000, Pages 160-166

  Santini, Gino ^a   Coser, Paolo ^b   Congiu, Angela Marina ^a   Salvagno, Luigi ^f   De Souza, Carmino ^c   Sertoli, Mario Roberto ^a   Olivieri, Attilio ^d   Chisesi, Teodoro ^e   Rubagotti, Alessandra ^a   Truini, Mauro ^a   Contu, Antonio ^f   Porcellini, Adolfo ^f   Zambaldi, Gino ^g   Nati, Sandro ^a   Marino, Gennaro ^a   Rizzoli, Vittorio ^h  

^a UNIVERSITY OF GENOA   (Italy)

^b S Maurizio Hospital   (Italy)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d Univ Ancona Le Torrette Hosp A   (Italy)

^e Venezia Hospital   (Italy)

^f Venezia Hospital ^*

^g Arco Hospital   (Italy)

^h UNIVERSITY OF PARMA   (Italy)

Author keywords

Aggressive non Hodgkin's lymphoma; Bone marrow involvement; High dose therapy

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN;

ADULT; ARTICLE; BONE MARROW METASTASIS; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; HUMAN; LEUKAPHERESIS; LEUKEMIA REMISSION; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BONE MARROW; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 0034091507     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1023-30.
2. Bennet JM, Cain KC, Glick JH, Johnson GJ, Ezdinli E, O'Connell MJ. The significance of bone marrow involvement in non-Hcdgkin's lymphoma: the Eastern Cooperative Oncology Group experience. J Clin Oncol 1986; 4: 1462-9.
3. Conlan MG, Bast M, Armitage JO, Weisenburger DD. Bone marrow involvement by non-Hodgkin's lymphoma: The clinical significance of morphologic discordance between the lymph node and bone marrow. Nebraska Lymphoma Study Group. J Clin Oncol 1990; 8:1163-72.
4. Stein RS, Greer JP, Flexner JM, et al. Large-cell lymphomas: clinical and prognostic features. J Clin Oncol 1990; 8:1370-9.
5. Vitolo U, Bertini M, Brusamolino E, et al. MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study. J Clin Oncol 1992; 10:219-27.
6. Yan Y, Chan WC, Weisenburger JR, et al. Clinical and prognostic significance of bone marrow involvement in patients with diffuse aggressive B-cell lymphoma. J Clin Oncol 1995; 13:1336-42.
7. Shipp MA, Harrington DP, Klatt MM, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 1986; 104:757-65.
8. Coiffier B, Gisselbrecht: C, Vose JM, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol 1991; 9:211-9.
9. A predictive model for aggressive non-Hodgkin's lymphomas. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329:987-94.
10. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13:588-95.
11. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333:1540-5.
12. Dreyfus F, Leblond V, Belander C, et al. Peripheral blood stem cell collection and autografting in high risk lymphomas. Bone Marrow Transplant 1992; 10: 409-13.
13. Santini G, Congiu AM, Nati S, et al. Mobilisation/ transplantation of peripheral blood progenitor cells for aggressive non-Hodgkin's lymphoma with marrow involvement. Leukemia 1996; 10(suppl 2):S88-91.
14. Vitolo U, Cortellazzo S, Liberati AM, et al. Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma. J Clin Oncol 1997; 15:491-8.
15. O'Reilly SE, Hoskins P, Klimo P, Connors JM. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Ann Oncol 1991; 2(suppl 1):17-23.
16. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49:2112-35.
17. Siena S, Bregni M, Brando B, et al. Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 1991; 77:400-9.
18. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials 1989; 10:1-10.
19. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc (B) 1958; 53:457-81.
20. Cabanillas F, Hagemeister FB, Mc Laughlin P, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 5:407-12.
21. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71:117-22.
22. Velasquez WS, Mc Laughlin P, Tucker S et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994; 12:1169-76.
23. Verdonck LF, Van Putten WL, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332:1045-51.
24. Martelli M, Vignetti M, Zinzani PL, et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 1996; 14:534-42.
25. Sharp JG, Kessinger A, Mann S, et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14:214-9.
26. De Vita VT, Jaffe ES, Mauch P, Longo DL. Lymphocytic lymphomas. In: De Vita VT, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Publ.; 1989. p. 1741-808.
27. Santini G, De Souza C, Congiu AM, et al. High-dose cyclophosphamide followed by autografting can improve the outcome of relapsed or resistant non-Hodgkin's lymphomas with involved or hypoplastic marrow. Leuk Lymphoma 1999; 33:321-30.
28. Kotasek D, Shepherd KM, Sage RE, et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumours. Bone Marrow Transplant 1992; 9:11-7.
29. Tarella C, Ferrero D, Bregni M, et al. Peripheral blood expansion of early progenitor cells after high-dose cyclophosphamide and rhGM-CSF. Eur J Cancer 1991; 27:22-7.
30. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691-7.